Frits Richard Rosendaal

Frits Richard Rosendaal

Auto-generated profile, based on publicly available information

Frits Richard Rosendaal

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2005 in JAMA
Verified
Journal Article
Open access
PDF file
JBJeanet W. Blom
Jeanet W. Blom
CDCarine J. M. Doggen
Carine J. M. Doggen
SOSusanne Osanto
Susanne Osanto
FRFrits R. Rosendaal
Frits R. Rosendaal
In 1868, Trousseau described the relationship between malignancy and venous thrombosis.1 Recent studies showed a 4% to 20% prevalence of malignancy in patients with deep venous thrombosis or pulmonary embolism.2,3 Although the risk of venous thrombosis in patients with cancer is evidently increased, studies that identify patients at highest risk of thrombosis are scarce. It is unclear what risks are for various types and stages of cancer.4,5

6 February 2006 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
JBJ. W. Blom
J. W. Blom
JVJ. P. M. Vanderschoot
J. P. M. Vanderschoot
MOM. J. Oostindiër
M. J. Oostindiër
SOS. Osanto
S. Osanto
FMF. J. M. VAN DER Meer
F. J. M. VAN DER Meer
FRF. R. Rosendaal
F. R. Rosendaal
Summary. Background: The incidence of venous thrombosis (VT) for cancer patients is increased compared with patients without cancer, but estimations of the incidence for different types of cancer have rarely been made because of the low incidence of various types of cancer. Large registries offer an opportunity to study the risk of VT in large cohorts of cancer patients, which is essential in decisions on prophylactic anti‐coagulant treatment. Methods: This cohort study estimates the incidence of VT in cancer patients by using record linkage of a Cancer Registry and an Anticoagulation Clinic database in the Netherlands. Cumulative incidences in patients with different types of malignancies were estimated. We calculated relative risks (RRs) in relation to the presence of distant metastases and treatment. Results: Tumors of the bone, ovary, brain, and pancreas are associated with the highest incidence of VT (37.7, 32.6, 32.1, and 22.7/1000/0.5 year). Patients with distant metastases had a 1.9‐fold increased risk [RRadj: 1.9; 95% confidence interval (CI): 1.6–2.3]. Chemotherapy leads to a 2.2‐fold increased risk (RRadj: 2.2; 95% CI: 1.8–2.7) and hormonal therapy leads to a 1.6‐fold increased risk (RRadj: 1.6; 95% CI: 1.3–2.1) compared with patients not using these treatment modalities. Patients with radiotherapy or surgery did not have an increased risk. Conclusions: We compared the overall incidences of VT in the first half year in our study to the risk of major bleeding as described in the literature. For patients with distant metastases, for several types of cancer, prophylactic anti‐thrombotic treatment could be beneficial.

13 August 2009 in BMJ
Verified
Journal Article
Open access
PDF file
AVA van Hylckama Vlieg
A van Hylckama Vlieg
FHF M Helmerhorst
F M Helmerhorst
JVJ P Vandenbroucke
J P Vandenbroucke
CDC J M Doggen
C J M Doggen
FRF R Rosendaal
F R Rosendaal
Objective To assess the thrombotic risk associated with oral contraceptive use with a focus on dose of oestrogen and type of progestogen of oral contraceptives available in the Netherlands. Design Population based case-control study. Setting Six participating anticoagulation clinics in the Netherlands (Amersfoort, Amsterdam, The Hague, Leiden, Rotterdam, and Utrecht). Participants Premenopausal women <50 years old who were not pregnant, not within four weeks postpartum, and not using a hormone excreting intrauterine device or depot contraceptive. Analysis included 1524 patients and 1760 controls. Main outcome measures First objectively diagnosed episodes of deep venous thrombosis of the leg or pulmonary embolism. Odds ratios calculated by cross-tabulation with a 95% confidence interval according to Woolf’s method; adjusted odds ratios estimated by unconditional logistic regression, standard errors derived from the model. Results Currently available oral contraceptives increased the risk of venous thrombosis fivefold compared with non-use (odds ratio 5.0, 95% CI 4.2 to 5.8). The risk clearly differed by type of progestogen and dose of oestrogen. The use of oral contraceptives containing levonorgestrel was associated with an almost fourfold increased risk of venous thrombosis (odds ratio 3.6, 2.9 to 4.6) relative to non-users, whereas the risk of venous thrombosis compared with non-use was increased 5.6-fold for gestodene (5.6, 3.7 to 8.4), 7.3-fold for desogestrel (7.3, 5.3 to 10.0), 6.8-fold for cyproterone acetate (6.8, 4.7 to 10.0), and 6.3-fold for drospirenone (6.3, 2.9 to 13.7). The risk of venous thrombosis was positively associated with oestrogen dose. We confirmed a high risk of venous thrombosis during the first months of oral contraceptive use irrespective of the type of oral contraceptives. Conclusions Currently available oral contraceptives still have a major impact on thrombosis occurrence and many women do not use the safest brands with regard to risk of venous thrombosis.

31 January 2008 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
EPE. R. Pomp
E. R. Pomp
ALA. M. Lenselink
A. M. Lenselink
FRF. R. Rosendaal
F. R. Rosendaal
CDC. J. M. Doggen
C. J. M. Doggen
Summary. Background: Venous thrombosis is one of the leading causes of maternal morbidity and mortality. Objective: In the MEGA study, we evaluated pregnancy and the postpartum period as risk factors for venous thrombosis in 285 patients and 857 control subjects. Patients/methods: Between March 1999 and September 2004, consecutive patients with a first episode of venous thrombosis were included from six anticoagulation clinics. Partners of patients and a random digit dialing group were included as control subjects. Participants completed a questionnaire and DNA was collected. Results: The risk of venous thrombosis was 5‐fold (OR, 4.6; 95% CI, 2.7–7.8) increased during pregnancy and 60‐fold (OR, 60.1; 95% CI, 26.5–135.9) increased during the first 3 months after delivery compared with non‐pregnant women. A 14‐fold increased risk of deep venous thrombosis of the leg was found compared with a 6‐fold increased risk of pulmonary embolism. The risk was highest in the third trimester of pregnancy (OR, 8.8; 95% CI, 4.5–17.3) and during the first 6 weeks after delivery (OR, 84.0; 95% CI, 31.7–222.6). The risk of pregnancy‐associated venous thrombosis was 52‐fold increased in factor V Leiden carriers (OR, 52.2; 95% CI, 12.4–219.5) and 31‐fold increased in carriers of the prothrombin 20210A mutation (OR, 30.7; 95% CI, 4.6–203.6) compared with non‐pregnant women without the mutation. Conclusion: We found an increased risk of venous thrombosis during pregnancy and the postpartum period, with an especially high risk during the first 6 weeks postpartum. The risk of pregnancy‐associated venous thrombosis was highly increased in carriers of factor V Leiden or the prothrombin 20210A mutation.

18 May 2005 in JAMA
Verified
Journal Article
Open access
PDF file
SCSverre Christian Christiansen
Sverre Christian Christiansen
TKTed Koster
Ted Koster
JVJan P. Vandenbroucke
Jan P. Vandenbroucke
FRFrits R. Rosendaal
Frits R. Rosendaal
The incidence rate of a first venous thrombosis is 1 to 2 events per 1000 patient-years.1-3 Venous thrombosis manifests mainly as deep venous thrombosis (DVT) and pulmonary embolism. Environmental risk factors include immobilization, surgery, malignancies, pregnancy, puerperium, and exogenous female hormones.4 Genetic abnormalities increasing the risk of a thrombotic event have been known for several decades and include deficiencies of the natural anticoagulants antithrombin, protein C, and protein S. Additional biochemical risk factors for a thrombotic event are factor V Leiden, prothrombin G20210A, high levels of factors VIII, IX, or XI, homocysteine, and fibrinogen.5-11 Knowledge of the risk of a thrombotic event recurrence and its determinants is relevant for clinical policy regarding screening for thrombophilia, duration of anticoagulant treatment, and prophylactic strategies in circumstances of increased risk.

1 January 2003 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
MAMorteza Abdollahi
Morteza Abdollahi
MCMary Cushman
Mary Cushman
FRFrits R. Rosendaal
Frits R. Rosendaal
Deep vein thrombosis (DVT) is a common disease with an annual incidence of about 1 in 1000. Many risk factors have already been studied, both genetic and acquired. It is unclear whether obesity affects thrombotic risk in unselected patients. Obesity is common, with a prevalence of 20-25% and may therefore have a considerable impact on the overall incidence of thrombosis. We evaluated the risk of thrombosis due to overweight and obesity using data from a large population based case-control study. Four hundred and fifty-four consecutive patients with a first episode of objectively diagnosed thrombosis from three Anticoagulation Clinics in the Netherlands were enrolled in a case-control study. Controls were matched on age and sex to patients and were introduced by the patients. All patients completed a standard questionnaire and interview, with weight and height measured under standard conditions. The associations of obesity with clotting factor levels were studied to investigate possible mechanisms. Obesity (BMI ≥30 kg/m2) increased the risk of thrombosis twofold (CI95: 1.5 to 3.4), adjusted for age and sex. Obese individuals had higher levels of factor VIII and factor IX, but not of fibrinogen. The effect on risk of obesity was not changed after adjustment for coagulation factors levels (fibrinogen, F VIII, F IX, D-dimer). The relative risk estimates were similar in different age groups and in both sexes, indicating a larger absolute effect in older age groups. Evaluation of the combined effect of obesity and oral contraceptive pills among women aged 15-45 revealed that oral contraceptives further increased the effect of obesity on the risk of thrombosis, leading to 10-fold increased risk amongst women with a BMI greater than 25 kg/m2 who used oral contraceptives. Obesity is a risk factor for deep vein thrombosis. Among women with a BMI greater than 25 kg/m2 the synergistic effect with oral contraceptives should be considered when prescribing these.